Why the study?
Current guidelines recommend ticagrelor for STEMI, but its efficacy and safety needed assessment specifically in elderly patients aged 75 years or older in an all-comers registry.
Does ticagrelor reduce major adverse cardiac and cerebrovascular events compared to clopidogrel in elderly patients (≥75 years) with STEMI?
Does ticagrelor reduce major adverse cardiac and cerebrovascular events compared to clopidogrel in elderly patients (≥75 years) with STEMI?
In elderly patients (≥75 years) with STEMI, ticagrelor was associated with a lower risk of major adverse cardiac and cerebrovascular events compared to clopidogrel, without a significant increase in bleeding events at 1 year.
No takes yet. Share an insight, caveat, or question.
Ticagrelor was associated with lower MACCE than clopidogrel in elderly STEMI; hypothesis-generating and requires randomized confirmation before changing practice.
Schmucker et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: